BTK

<!-- Name:DistributionId Value:8808477 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK mutations conferring resistance to both…

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65…

BOSTON -- A form of chronic hives improved quickly and significantly in response to treatment with a novel Bruton's tyrosine kinase (BTK) inhibitor, a multicohort dose-finding study…

SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and…

— HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED — — HMPL-760 is HUTCHMED’s fifth candidate in clinical development for hematological malignancies, including amdizalisib and HMPL-523…

There is little question that the development of Bruton tyrosine kinase (BTK) inhibitors has changed the treatment landscape for Waldenström macroglobulinemia patients and their…

SANTA CLARA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the start…

Evobrutinib, a highly selective Bruton's tyrosine kinase inhibitor (BTK) targeting B cells and myeloid cells, reduced the volume of slowly expanding lesions (SELs) in people with…

Tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, reduced new, active brain lesions in people with relapsing multiple sclerosis (MS), a…